Neurology | Home | MIMS Malaysia

Midazolam nasal spray a promising treatment option in patients with seizure clusters

Jairia Dela Cruz, an hour ago

Midazolam nasal spraydelivers prompt and prolonged seizure control with a favourable safety profile in the outpatient treatment of patients experiencing a seizure cluster, according to the results of the phase III ARTEMIS-1* trial.

Faster cognitive decline seen after incident coronary events

Stephen Padilla, 4 hours ago

Accelerated cognitive decline is significantly associated with incident coronary heart disease (CHD) after, but not before or immediately following, ischaemic events, suggests a recent study.

Longer Parkinson’s duration leads to greater caregiver burden

Tristan Manalac, 2 days ago

Patients with Parkinson’s disease (PD) who had been suffering from the disease for a longer time and those with greater levodopa-related motor complications tend to require more of their caregivers, according to a recent Singapore study.

Weak morning BP surge in healthy nondippers tied to autonomic neural activity

3 days ago

In young, healthy individuals who do not display nocturnal blood pressure (BP) dipping, a weaker morning BP surge (MBPS) is inversely correlated with autonomic neural activity, a recent study has found.

Asian AF patients with supranormal renal function fare better with NOACs vs warfarin

Jairia Dela Cruz, 5 days ago

Nonvitamin K antagonist oral anticoagulants (NOACs) perform better than warfarin for stroke prevention in Asian patients with nonvalvular atrial fibrillation (AF) and supranormal renal function, according to a study.

Chronic hyperglycaemia may be detrimental to developing brain

Elaine Soliven, 6 days ago

Children with early-onset type 1 diabetes (T1D) and poor glycaemic control have a slower growth of brain regions associated with sensory processing and cognition compared with nondiabetic controls, according to a longitudinal study of brain growth by the DirecNet*.

Shifting paradigms in MS management: Early, optimized interventions improve patient outcomes

04 May 2018

Multiple sclerosis (MS) is one of the most common neurological disorders – affecting over 2.3 million people globally – and it is the leading cause of nontraumatic disability in young adults. However,the availability of supportive resources and services for people with MS is scarce in many regions of the world. In Malaysia, the prevalence of MS is estimated at 2-3/100,000; the current Malaysian clinical practice guidelines on the management of MS recommend disease modifying agents, such as interferon-β and teriflunomide, as first-line therapeutic agents. In this article, Dr Singer - in partnership with Sanofi and the Malaysian Society of Neurosciences - shares his insights into managing MS dynamically, highlighting the importance of early intervention in improving patient outcomes.

Management of dementia beyond cognition – a deeper look into BPSD and CVD

13 Dec 2017

At the Schwabe-Menarini lunch symposium of the 11^th International Congress of the Asian Society AgainstDementia (ASAD) 2017 held in Bangkok, Thailand, Professor Ralf Ihl highlighted the role of standardized Gingko biloba extract EGb 761^®for the treatment of patients with behavioural and psychological symptoms of dementia (BPSD). Meanwhile, Associate Professor Nagaendran Kandiah presented clinical findings on the association between cerebrovascular disease (CVD) and dementia, and emphasized the role of EGb 761^®in the management of dementia with CVD.

Drug and non-drug approaches to managing tension-type headache

01 Jul 2017

At the recent launch of Nurofen^® Express by Reckitt Benckiser Malaysia, Ms Joyce McSwan spoke on the importance of managing tension-type headache (TTH), highlighting the roles of drug and non-drug approaches in improving treatment outcomes.

Hypertension and cholesterol lowering interventions do not reduce cognitive decline

Roshini Claire Anthony, 22 Nov 2016

Blood pressure lowering medications and statins do not prevent cognitive and functional decline in elderly patients, according to results of the HOPE-3 trial* presented at the Scientific Sessions of the American Heart Association (AHA 2016) held recently in New Orleans, Louisiana, US.

An uncommon cause of hyperthyroidism

Dr. Rose Zhao-Wei Ting, 16 Nov 2016

A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.

Evobrutinib may reduce lesions in relapsing MS

Roshini Claire Anthony, 28 May 2019

The oral BTK* inhibitor evobrutinib at a dose of 75 mg/day reduced the number of gadolinium-enhancing lesions in patients with relapsing multiple sclerosis (MS), according to a phase II trial presented at AAN 2019.

Rapid relief of migraine pain with orally dissolving rimegepant

Pearl Toh, 22 May 2019

A new orally dissolving tablet (ODT) formulation of rimegepant showed rapid onset of action and sustained benefits in terms of pain relief and symptom improvement in patients with acute migraine, the 303 study finds.

Novel 3-drug combo offers hope for Charcot-Marie-Tooth patients

Pearl Toh, 21 May 2019

A novel three-drug cocktail, PXT3003, reduces disability in patients with Charcot-Marie-Tooth Type 1A disease (CMT1A) along with a favourable safety profile, according to the PLEO-CMT study presented at AAN 2019, providing hope for a rare disease which so far has no cure.

Eculizumab cuts relapse risk in NMOSD

Pearl Toh, 20 May 2019

The terminal complement inhibitor eculizumab significantly lowered relapse risk in patients with neuromyelitis optical spectrum disorder (NMOSD) who were positive for aquaporin-4 antibodies (AQP4-IgG) compared with placebo, according to the PREVENT* study presented at AAN 2019.

Cannabidiol may halve seizure risk in Dravet syndrome

Roshini Claire Anthony, 16 May 2019

A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).

Isradipine disappoints in Parkinson’s disease

Roshini Claire Anthony, 15 May 2019

Use of the antihypertensive drug isradipine did not reduce the progression of Parkinson’s disease, according to the STEADY-PD III* study presented at the American Academy of Neurology annual meeting (AAN 2019).